dc.contributor.author | Thieblemont, C | |
dc.contributor.author | Phillips, T | |
dc.contributor.author | Ghesquieres, H | |
dc.contributor.author | Cheah, CY | |
dc.contributor.author | Clausen, MR | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Do, YR | |
dc.contributor.author | Feldman, T | |
dc.contributor.author | Gasiorowski, R | |
dc.contributor.author | Jurczak, W | |
dc.contributor.author | Kim, TM | |
dc.contributor.author | Lewis, DJ | |
dc.contributor.author | van der Poel, M | |
dc.contributor.author | Poon, ML | |
dc.contributor.author | Cota Stirner, M | |
dc.contributor.author | Kilavuz, N | |
dc.contributor.author | Chiu, C | |
dc.contributor.author | Chen, M | |
dc.contributor.author | Sacchi, M | |
dc.contributor.author | Elliott, B | |
dc.contributor.author | Ahmadi, T | |
dc.contributor.author | Hutchings, M | |
dc.contributor.author | Lugtenburg, PJ | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2023-03-09T12:54:49Z | |
dc.date.available | 2023-03-09T12:54:49Z | |
dc.date.issued | 2022-12-22 | |
dc.identifier.citation | Journal of Clinical Oncology, 2022, pp. JCO2201725 - | en_US |
dc.identifier.issn | 0732-183X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5717 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.doi | 10.1200/JCO.22.01725 | |
dc.description.abstract | PURPOSE: Epcoritamab is a subcutaneously administered CD3xCD20 T-cell-engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes. PATIENTS AND METHODS: In the dose-expansion cohort of a phase I/II study (ClinicalTrials.gov identifier: NCT03625037), adults with relapsed or refractory CD20+ large B-cell lymphoma and at least two prior therapy lines (including anti-CD20 therapies) received subcutaneous epcoritamab in 28-day cycles (once weekly step-up doses in weeks 1-3 of cycle 1, then full doses once weekly through cycle 3, once every 2 weeks in cycles 4-9, and once every 4 weeks in cycle 10 and thereafter) until disease progression or unacceptable toxicity. The primary end point was overall response rate by the independent review committee. RESULTS: As of January 31, 2022, 157 patients were treated (median age, 64 years [range, 20-83]; median of three [range, 2-11] prior therapy lines; primary refractory disease: 61.1%; prior chimeric antigen receptor (CAR) T-cell exposure: 38.9%). At a median follow-up of 10.7 months, the overall response rate was 63.1% (95% CI, 55.0 to 70.6) and the complete response rate was 38.9% (95% CI, 31.2 to 46.9). The median duration of response was 12.0 months (among complete responders: not reached). Overall and complete response rates were similar across key prespecified subgroups. The most common treatment-emergent adverse events were cytokine release syndrome (49.7%; grade 1 or 2: 47.1%; grade 3: 2.5%), pyrexia (23.6%), and fatigue (22.9%). Immune effector cell-associated neurotoxicity syndrome occurred in 6.4% of patients with one fatal event. CONCLUSION: Subcutaneous epcoritamab resulted in deep and durable responses and manageable safety in highly refractory patients with large B-cell lymphoma, including those with prior CAR T-cell exposure. | |
dc.format | Print-Electronic | |
dc.format.extent | JCO2201725 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | American Society of Clinical Oncology (ASCO) | en_US |
dc.relation.ispartof | Journal of Clinical Oncology | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.title | Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-11-15 | |
dc.date.updated | 2023-03-09T12:53:47Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1200/JCO.22.01725 | en_US |
rioxxterms.licenseref.startdate | 2022-12-22 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36548927 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1200/jco.22.01725 | |
icr.researchteam | Medicine (RMH) | en_US |
dc.contributor.icrauthor | Cunningham, David | |
icr.provenance | Deposited by Mr Arek Surman on 2023-03-09. Deposit type is initial. No. of files: 1. Files: jco.22.01725.pdf | |